Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEVYE for Contact Lens Discomfort in Dry Eye Disease
NCT07904728Recruiting
- Sponsor
- Ocular Aesthetics
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclosporine 2% ophthalmic solution in dry eye disease (DED) and Contact lens discomfort (CLD), sponsored by Ocular Aesthetics. Primary endpoint: Contact Lens Dry Eye Questionnaire-8 at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)Contact lens discomfort (CLD)
Beyond the preview
Go deeper on NCT07904728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904728.